[Form 4] Inmune Bio, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Inmune Bio, Inc. (INMB) director Marcia Allen reported a repricing of her stock options, following stockholder approval effective November 18, 2025. Certain existing options granted under the company’s 2017, 2019 and 2021 stock incentive plans had their exercise price reduced to $1.50 per share, matching the Nasdaq closing price of Inmune Bio’s common stock on the repricing date. The filing shows prior options with higher exercise prices, including awards at $3.91, $7.92, $9.74, $17.49, $24.82 and $5.05, being adjusted so that the same numbers of underlying shares remain, but at the new exercise price. All other terms of these options, such as vesting schedules and expiration dates, remain unchanged, and the awards continue to be tied to Allen’s ongoing service with the company.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ALLEN MARCIA

(Last) (First) (Middle)

C/O INMUNE BIO INC.

225 NE MIZNER BLVD., SUITE 640

(Street)

BOCA RATON FL 33432

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Inmune Bio, Inc. [ INMB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$3.91	11/18/2025		D(1)			108,000	(2)	11/24/2029	Common Stock	108,000	(1)	0	D
Stock Option (right to buy)	$1.5	11/18/2025		A(1)		108,000		(2)	11/24/2029	Common Stock	108,000	(1)	108,000	D
Stock Option (right to buy)	$24.82	11/18/2025		D(1)			15,975	(2)	01/18/2031	Common Stock	15,975	(1)	0	D
Stock Option (right to buy)	$1.5	11/18/2025		A(1)		15,975		(2)	01/18/2031	Common Stock	15,975	(1)	15,975	D
Stock Option (right to buy)	$17.49	11/18/2025		D(1)			19,025	(2)	06/21/2031	Common Stock	19,025	(1)	0	D
Stock Option (right to buy)	$1.5	11/18/2025		A(1)		19,025		(2)	06/21/2031	Common Stock	19,025	(1)	19,025	D
Stock Option (right to buy)	$7.92	11/18/2025		D(1)			35,000	(2)	03/20/2032	Common Stock	35,000	(1)	0	D
Stock Option (right to buy)	$1.5	11/18/2025		A(1)		35,000		(2)	03/20/2032	Common Stock	35,000	(1)	35,000	D
Stock Option (right to buy)	$9.74	11/18/2025		D(1)			35,000	(2)	02/15/2033	Common Stock	35,000	(1)	0	D
Stock Option (right to buy)	$1.5	11/18/2025		A(1)		35,000		(2)	02/15/2033	Common Stock	35,000	(1)	35,000	D
Stock Option (right to buy)	$5.05	11/18/2025		D(1)			32,500	(2)	12/04/2034	Common Stock	32,500	(1)	0	D
Stock Option (right to buy)	$1.5	11/18/2025		A(1)		32,500		(2)	12/04/2034	Common Stock	32,500	(1)	32,500	D
Stock Option (right to buy)	$9.92	11/18/2025		D(1)			12,500	(2)	05/13/2034	Common Stock	12,500	(1)	0	D
Stock Option (right to buy)	$1.5	11/18/2025		A(1)		12,500		(2)	05/13/2034	Common Stock	12,500	(1)	12,500	D

Explanation of Responses:

1. Effective as of November 18, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2017 Stock Incentive Plan (the "2017 Plan"), 2019 Stock Incentive Plan (the "2019 Plan"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the "2021 Plan") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

2. This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

	/s/ Marcia Allen	11/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Inmune Bio (INMB) disclose in this Form 4 filing?

The filing reports that director Marcia Allen had several existing stock option grants repriced, with their exercise price reduced to $1.50 per share, effective November 18, 2025, while retaining the same number of underlying shares and other existing terms.

Why were Marcia Allen’s Inmune Bio stock options repriced to $1.50?

The options were adjusted as part of a one-time repricing approved by Inmune Bio’s stockholders, which reset the exercise price of certain outstanding options to $1.50, the closing price of the company’s common stock on The Nasdaq Capital Market on the repricing date.

Which Inmune Bio stock incentive plans are involved in this option repricing?

The repriced options were originally granted under Inmune Bio’s 2017 Stock Incentive Plan, 2019 Stock Incentive Plan and the Second Amended and Restated 2021 Stock Incentive Plan, and continue to be governed by those plans.

How did the repricing affect the terms of Marcia Allen’s Inmune Bio options?

Only the exercise price of the affected options was changed to $1.50 per share. The filing states that all other terms and conditions, including vesting provisions and the term of the options, remain in full force and effect.

What were some of the previous exercise prices of the repriced Inmune Bio options?

The report lists prior option grants with higher exercise prices, including awards at $3.91, $7.92, $9.74, $17.49, $24.82 and $5.05, which were adjusted so that the same number of shares are now exercisable at $1.50.

Does Marcia Allen’s continued service affect these Inmune Bio option awards?

Yes. The filing notes that the options become exercisable in line with the existing vesting schedule specified in the award agreements and remain subject to her continued service with Inmune Bio as of each vesting date.